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Albumin homeostasis in patients undergoing continuous ambulatory
peritoneal dialysis. Albumin and protein removal rates were studied in
18 patients undergoing continuous ambulatory peritoneal dialysis(CAPD). In nine patients simultaneous studies of albumin distribution
and turnover were performed. Total albumin loss was 4.23 1.42 gIl .73
m2/24 hr; total protein removed was 8.79 4.21 g/l.73 m2/24 hr.
Although these values were well within the range for severe nephrosis,
serum albumin concentration remained nearly normal, 3.7 0.5 gldl.
Plasma albumin mass, 120.0 25.2 gIl.73 m2, and total albumin mass,
249 29.1 gIl.73 m2, did not differ from those of the control group.
Compared with the control group, patients had reduced albumin
catabolism, 9.76 1.74 gIl .73 m2/24 hr versus 13.8 0.77 g/l.73 m2124
hr (P < 0.001). Within the patient group albumin synthesis increased
with increased albumin loss. Serum albumin concentration correlated
negatively with albumin losses (P < 0.001). The CAPD patients
maintained albumin homeostasis through decreased albumin catabolism
and increased synthesis. All major albumin pools were maintained
despite massive albumin loss.
Homéostasie de l'albumine chez des malades en dialyse péritonéale
continue ambulatoire. Les vitesses de disparition de l'albumine et des
protéines ont été étudiées chez 18 malades en dialyse péritonéale
continue ambulatoire (CAPD). Chez neuf malades, des etudes simultan-
Ces de la distribution et du renouvellement de l'albumine ont Cté
effectuées. La perte totale en albumine était de 4,23 1,42 g/l .73 m2/24
hr; Ia quantité totale de protéines enlevée était de 8,79 4,21 g/1.73
m2/24 hr. Bien que ces valeurs soient tout a fait dans l'ordre de grandeur
de celles des nephroses sévCres, la concentration d'albumine serique
restait pratiquement normale, 3,7 0,5 g/dl. La masse d'albumine
plasmatique, 120,0 25,2g/l,73 m2, et Ia masse d'albumine totale, 249
29,1 g/1,73 m2 n'étaient pas différentes de celles du groupe contrôle.
Par rapport au groupe contrôle, les malades avalent un catabolisme de
l'albumine réduit, 9,76 1,74 g/1,73 m2/24 hr contre 13,8 0,77 g/1,73
m2/24 hr (P < 0,001). Dans le groupe de malades, Ia synthese d'albu-
mine s'est élvée avec l'augmentation de Ia perle d'albumine. La
concentration d'albumine sérique était négativement corrélée avec les
pertes d'albumine (P <0,001). Les malades en CAPD maintenaient une
homéostasie de l'albumine grace a une diminution du catabolisme et a
une augmentation de Ia synthèse d'albumine. Les principaux comparti-
ments de l'albumine étaient maintenus, malgré une fuite massive
d'albumine.
Since its introduction in 1979, continuous ambulatory perito-
neal dialysis (CAPD) has been widely accepted as a modality
for the treatment of endstage renal disease. Loss of protein
during this procedure comparable to that that occurs in severe
nephrosis has been documented by several investigators [1, 2].
The homeostatic mechanisms triggered in response to albumin
loss in patients undergoing CAPD have not been reported. Only
modest hypoalbuminemia develops in CAPD patients [2] corn-
pared with the severe hypoalbuminemia that is present in
nephrotic patients. We were therefore especially interested in
studying albumin and protein removal rates and the effect of
albumin removal on serum albumin concentration, distribution,
and catabolism in patients undergoing CAPD.
Methods
All patients entering or on the CAPD program at the Univer-
sity of California Renal Center at San Francisco General
Hospital Medical Center and the San Francisco Veterans
Administration Hospital, San Francisco, California, were asked
to participate in the study. Informed consent was obtained from
all patients and control subjects. Patients who had exit site
leaks or severe infections were excluded from the study. One
patient dropped out of the study because of the development of
a peritoneal pleural fluid communication. The relationship
between serum albumin concentration and peritoneal albumin
loss was studied in the 18 dialysis patients. Albumin turnover
and distribution were studied in nine of these patients. The
patients were not receiving prednisone or anabolic steroid
therapy. The causes of renal failure are shown in Table 1.
Volunteer subjects without proteinuria or known renal abnor-
malities constituted a control group and were studied as outpa-
tients. Clinical characteristics of this group are shown in Table
2.
Patients were admitted to the General Clinical Research
Center at San Francisco General Hospital Medical Center on
the day before initiation of the study. A nutritional history was
obtained by a dietitian. The patients were then placed on a fixed
metabolic diet that was developed from information obtained
from the nutritional history. The caloric intake, including
dialysate glucose absorption, was designed to be isocaloric,
100 calories per day, with the previous dietary record. All
subjects received a blocking dose of Lugol's solution on the
first day of study. 1251-Albumin (Mallinkrodt, Inc., St. Louis,
Missouri), 10 pCi, was injected into a peripheral vein. A total of
six blood samples were obtained on day 1(3 mllsample) at 5, 15,
and 60 mm and 2, 5, and 10 hr. An additional sample was drawn
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Table 1. Clinical characteristics of patients undergoing continuous ambulatory peritoneal dialysis
Serum characteristics
Blood Treatment for Time on pen-
urea Calorie Dietary endstage renal toneal
Patient Age/Sex nitrogen Creatinine Hematocrit intake protein intake disease dialysis
no. years Renal disease mg/di mg/di % Kcal/kg/day g/kg/day months months
1 66/F Unknown 81 8.8 22 33 1.1 1 1
2 61/M Polycystic 82 9.7 46 38 1.4 1
3 38/M Diabetes mellitus 76 20.5 25 38 1.4 18 18
4 42/M Diabetes mellitus 62 10.2 24 42 1.2 1
5 52!M Diabetes mellitus 73 7.9 29 38 1.35 4 4
6 30/M Chronic glomerular
nephritis 108 9.3 22 42 1.52 60 1
7 74/M Unknown 67 9.4 34 31 1.03 39 38
8 62/M Unknown 103 9.9 35.2 20 0.85 6 2
9 39/M Unknown 81 8.6 25.8 43 1.53 1
10 29/F Diabetes mellitus 48 6.0 21 44 2.0 37 1
11 52/F Unknown 51 17.0 20 39 1.5 60 1
12 51/M Chronic glomerular
nephritis 60 15.3 19 27 0.8 61
13 53/M Chronic glomerular
nephritis 89 11.2 35 50 1.5 108
14 29/M Diabetes mellitus 125 18.3 23 37 1.5 18 3
15 55/M Chronic glomerular
nephritis 76 20.3 27 64 1.5 96
16 37!M Obstructive uropathy 85 19.5 27 26 0.97 48
17 67/F Unknown 93 12.0 31 34 1.5 32 1
18 63/F Unknown 73 15.1 32 40 1.33 77 1
Table 2. Clinical characteristics and albumin homeostatic data for five control subjects
Albumin
Extra- synthe- Frac-
vascular sis/cata- tional
Blood Plasma Plasma Total albumin bolism, catabo-Pa- Age! Surface urea Creati- Hema- Serum volume, albumin albumin mass, g g!24 hr lism
tient sex Weight area nitrogen nine tocrit albumin liter mass, g mass, g (g!1.73 PAM (g/24 hr/
no. years kg m2 mg/dl mg/dl % g/dl (mi/kg) (g/J.73 m2) (g/1.73 m2) m2) EVAM 1.73 m2)
% PAM!
24 hr
1 39/M 75.0 1.92 19.6 0.9 41 4.51 2.314 104.0 271 166 0.627 14.97 14.4
(30.9) (93.7) (244) (150) (13.49)2 41/M 82.3 2.06 17.3 1.0 43 4,49 3.149 141.0 314 172 0.820 16.35 11.6
(38.3) (118) (264) (144) (13.73)3 41/M 59.0 1.72 8.0 0.9 45 4.64 2.170 100.0 237 136 0.735 14.71 14.7
(36.7) (101) (238) (137) (14.79)4 39/M 75.0 2.00 17.4 1.0 43 4.80 2.807 135.0 353 218 0.619 16.48 12.2
(37.4) (117) (305) (189) (14.25)
5 30/F 56.4 1.63 12.7 0.8 38 4.73 2.288 108.0 264 156 0.692 12.02 11.1
(40.6) (115) (280) (165) (12.76)
Abbreviations: EVAM, extravascular albumin mass; PAM, plasma albumin mass.
24 hr after the injection and daily for 2 weeks and then twice
weekly for a total time of 4 weeks from the time of injection.
Blood was obtained from control subjects twice weekly after
the initial 48-hr period.
Dialysate and urine were collected daily for the measurement
of total protein and albumin. Each blood sample was also
assayed for total protein and albumin. Total '251-radioactivity
per milliliter and per milligram of albumin was measured in each
of these fluids.
Laboratory methods. Total protein in serum, dialysate, and
urine were measured by the method of Bradford [3]. Albumin
was determined by immunoelectrophoresis [41 in all samples
and in addition by the bromcresol green dye indicator in serum
samples [51. To determine the specific radioactivity of 125!
bound to albumin, each dialysis sample was passed through an
Affi-Gel Blue affinity column obtained from BioRad, Rich-
mond, California. The gel was suspended in an equal volume of
20 m potassium phosphate, pH 7.1. The slurry was placed in a
disposable plastic column (BioRad). A total bed volume was 0.5
ml. Each column was washed with 1.5 ml of the phosphate
buffer. Twenty milliliters of dialy sate were then slowly applied
to the column. The column was washed with several volumes of
the phosphate buffer and the eluate was discarded. Albumin
was eluted with 1 ml of 8 M urea in phosphate buffer. The eluate
was dialyzed extensively against four changes of distilled water
and then lyophilized. Purity of albumin was confirmed by
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Table 3. Parameters of albumin homeostasis in 18 patients undergoing CAPD
Extra Dialysis Urinary Total
Plasma Total vascular protein protein protein
Plasma albumin albumin albumin loss, loss, loss,
Serum volume, mass, g mass, g mass, g g/24 hr g/24 hr g124 hr
Patient
no.
Weight
kg
Surface
area m2
albumin
g/di
liter
(mi/kg)
(gIl .73
m2)
(gIl .73
m2)
(gIl 73
m2)
PAM
EVAM
(g/24 hr/
1.73 m2)
(g/24 hr/
1.73 m2)
(g124 hr/
1.73 m2)
1 53.4 1.32 3.9 2.29
(42.8)
90.0
(117)
193
(252)
103
(135)
0.874 6.48
(8.49)
0.595
(0.779)
7.08
(9.27)
2 65.5 1.77 4.0 2.99
(45.7)
126
(123)
264
(258)
138
(135)
0.913 9.53
(9.32)
0.611
(0.598)
10.14
(9.92)
3 64.8 1.76 3.7 3.69
(55.6)
133
(131)
315
(310)
182
(180)
0.731 13.1
(12.9)
0.187
(0.184)
13.3
(13.1)
4 80.0 2.06 2.6 8.14
(102)
210
(176)
327
(273)
117
(97.3)
1.745 7.94
(6.66)
12.17
(10.22)
20.1
(16.9)
5 77.7 2.00 3.8 2.65
(34.1)
101
(87.4)
269
(232)
168
(145)
0.601 6.44
(5.57)
1.03
(0.891)
7.47
(6.46)
6 54.5 1.65 3.9 2.90
(53.2)
113
(119)
204
(214)
91
(95.3)
1.242 3.44
(3.60)
0
(0)
3.44
(3.61)
7 69.0 1.86 3.6 2.64
(38.3)
95
(93.4)
246
(228)
151
(140)
0.629 9.30
(8.65)
0.564
(0.525)
9.86
(9.18)
8 85.1 1.88 4.5 2.81
(32.9)
126
(116)
248
(228)
122
(112)
1.03 5.78
(5.32)
0.22
(0.20)
6.00
(5.52)
9 62.8 1.66 3.7 3.19
(50.9)
115
(120)
236
(246)
121
(126)
0.95 3.41
(3.55)
1.56
(1.63)
4.97
(5.18)
10 45.0 1.45 2.4 19.8
(23.6)
0
(0)
19.8
(23.6)
11 62.5 1.69 3.3 13.0
(13.31)
0
(0)
13.0
(13.3)
12 77.2 1.86 3.7 13.9
(13.0)
0
(0)
13.9
(13.0)
13 62.5 1.80 3.3 18.9
(18.2)
0
(0)
18.9
(18.2)
14 85.0 2.10 4.1 14.5
(11.94)
2.01
(1.66)
16.5
(13.6)
15 55.9 1.68 3.9 8.8
(9.06)
0
(0)
8.8
(9.06)
16 95.5 2.20 4.1 11.7
(9.20)
0.546
(0.430)
12.2
(9.63)
17 55.5 1.60 3.5 8.8
(9.52)
0.180
(0.197)
8.98
(9.72)
18 62.3 1.71 4.4 9.7
(9.81)
0
(0)
9.7
(9.81)
discontinuous gel electrophoresis [6]. Each sample was then
counted in a spectrometer (Model 3002, Auto Gamma Spec-
trometer, Packard, Downers Grove, Illinois) with a counting
efficiency of 71%.
Calculations of albumin catabolism and distribution. Be-
cause inorganic iodide clearance would be anticipated to be
prolonged in dialysis patients compared with subjects with
normal renal function, inorganic iodide was removed from each
serum sample by passage through a column of BioRad AG 1X8
(BioRad) resin (C1 form) to remove free 125J The eluate was
assayed for albumin [4, 5] and counted for 1251 This allowed us
to determine the specific radioactivity of serum albumin unaf-
fected by retained inorganic iodide. All 125! counts were con-
firmed to be precipitable by 10% trichloroacetic acid. 125j
disintegrations per minute were determined per milliliter of
serum normalized to the mean serum albumin concentration for
each patient.
Calculations. The logarithm of the counts bound to albumin
per milliliter of plasma is plotted versus time. The area under
the resulting curve (AUC) is computed in two parts using the
log trapezoidal equation. The area from C0 to the last measured
concentration Ciast is integrated using the following equation.
The area under each segment is determined for each of the C,
and the areas are then added together.
(C — C_1) (i.T) (1)
in C — 1nC_1
The area from Ciast to infinity is integrated by the equation:
Ciast
13
where 13 is the final time constant, ln2/T112, estimated by fitting
four or more data points in the final log-linear portion of the
curve to a monoexponential equation. The terminal portion
made up approximately 20% of the total AUC where AUC was
the total area [7]:
(2)
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Table 3. (Continued)
Total Frac- Frac-
Dialysis
albumin
Urinary
albumin
external
albumin
Albumin
synthe-
Albumin
catabo-
tional
elimina-
tional
catabo-
loss, loss, loss, sis, g/24 lism, tion rate lie rate
g/24 hr
(g/24 hr/
1.73 m2)
g/24 hr
(g/24 hr/
1.73 m2)
g/24 hr
(g/24 hr/
1.73 m2)
hr (g/24
hr/I .73
m2)
g/24 hr
(g/24 hr/
1.73 in2)
(%
PAM/24
hr)
(%
PAM/24
hr)
2.09 0.175 2.27 8.71 6.44 9.68 7.16
(2.74) (0.229) (2.98) (11.41) (8.43)
3.48 0.206 3.69 17.28 13.59 13.7 10.8
(3.40) (0.202) (3.60) (16.89) (13.29)
4.86 0.08 4.94 16.69 11.75 12.5 8.84
(4.78) (0.08) (4.86) (15.91) (11.05)
4.60 4.28 8.88 21.67 12.79 10.3 6.09
(3.86) (3.61) (7.47) (18.19) (10.72)
3.68 0.694 4.37 15.4 11.03 15.2 10.9
(3.18) (0.601) (3.78) (13.32) (9.54)
2.98 0 2.98 11.33 8.35 10.0 7.4
(3.13) (0) (3.13) (11.88) (8.75)
5.53 0.054 5.58 15.16 9.58 16.0 10.1
(5.15) (0.050) (5.20) (14.10) (8.90)
3.50 0.220 3.72 14.33 10.61 11.40 8.42
(3.22) (0.20) (3.42) (13.19) (9.77)
2.84 0.673 3.51 10.60 7.09 9.22 6.17
(2.96) (0.701) (3.66) (11.05) (7.39)
11.0 0 11.0
(13.1) (0) (13.12)
9.0 0 9.0
(9.21) (0) (9.21)
5.0 0 5.0
(4.65) (0) (4.65)
9.5 0 9.5
(9.13) (0) (9.13)
6.80 0.95 7.75
(5.60) (0.786) (6.39)
3.70 0 3.7
(3.81) (0) (3.81)
6.8 0.113 6.91
(5.35) (0.104) (5.45)
3.3 0.016 3.3
(3.54) (0.018) (3.56)
4.8 0 4.80
(4.86) (0) (4.86)
AUC L Cdt. (3)
The counts per minute per milliliter of plasma bound to albumin
were used in these calculations. The dose (D) (total counts
injected) divided by AUC is the clearance of albumin in
milliliters per hour [8]. The product of the clearance and the
mean serum albumin concentration is then the total removal
rate of albumin by all routes. When the linear trapezoidal rule
was used as the method of integration, rather than the log
trapezoidal rule, the results differed by less than 1%, since the
time intervals between sampling were much less than the half-
life. The subjects' weight, with the exception of patient no. 4,
and serum albumin concentration remained constant through-
out the course of these measurements. We therefore made the
assumption that these patients were in a steady state so that
total albumin turnover was equal to the average rate of albumin
synthesis. In the absence of exudative skin lesions or a protein-
losing enteropathy, albumin is removed only by catabolism,
urinary loss, and peritoneal losses. The metabolic component of
albumin loss is due to endogenous catabolism of albumin and is
then total loss minus extracorporeal losses and is defined
Albumin catabolism =
D/AUC x (serum albumin concentration)
— (urinary loss + peritoneal loss) (4)
Steady state volume of distribution was measured by the
method of Benet and Galeazzj [9]. In this method the area under
the first moment curve (AUMC) of the plasma 115J concentra-
tion is defined as the area under the curve of the product of
time, t, and plasma concentration, C, from zero time to infinity
[7],
AUMC = j tCdt
The steady state volume of distribution is then [7]
VD dose x [J tCdt] — dose [AUMCØ —* ce]—
[f000Cdt]2 [AUC0
(5)
(6)
This determination is valid when elimination occurs exclusively
from the central (plasma) compartment of a multicompartment
model [9], but that is true of all other methods used for
determining the apparent volume of distribution of a substance.
The assumption is also valid with respect to albumin metabo-
lism [101.
The integral of AUMCO — is again done in two parts. We
have chosen to use the log trapezoidal equations again rather
than the linear trapezoidal equations, although the difference in
results between the two methods is again quite small in this
case.
The area from C0 to Clast is calculated by summing the areas
for n = 1 to n = last measured [7]:
tn Cn — tn_I C,_1 C — C_1
(lI&) in (Cn/Cn_i)
— [(i/zt) ln (CIC_1)]2
The area from Ciast at tiast to co is given by [7]:
tiast Ciast + Ciast
13 /32
(7)
(8)
Plasma volume is determined after bolus injection of 125j human
serum albumin intravenously. Blood samples obtained at 5, 15,
and 60 mm are assayed for counts per minute per milliliter. The
results are extrapolated to zero time using least squares regres-
sion to a semilogarithmic plot. Plasma albumin mass is plasma
volume times serum albumin concentration.
Fractional albumin catabolism is defined as the portion of the
plasma albumin pool catabolized per 24 hr [11—13]; similarly,
fractional albumin elimination rate is defined as the portion of
the plasma albumin pool eliminated per 24 hr. Both are ex-
pressed as percent. Total albumin elimination is equal to
albumin catabolism plus total external albumin loss. Total
albumin mass is then defined as plasma albumin concentration
times VD55. Extravascular albumin mass is total albumin mass
— plasma albumin mass. Student's t test was used for analysis
of unpaired data.
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Table 4. Comparison of albumin homeostasis in patients undergoing CAPD with normal control patients and with nephrotic patients
Significance
nephrotic
Significance patients
Normal control normal Nephrotic compared
group CAPD patients compared patients to CAPD
Parameter N = 5 N = 9 to CAPD N = 30 patients
Age, years 38.00 4.6 50.0 14.1 NS
Weight, kg 69.5 11.3 68.1 11.0 NS 67.5 11.25 NS
Serum albumin, gIdi 4.6 0.3 3.7 0.5 <0.005 1.54 0.68 <0.001
Plasma volume, mi/kg 36.8 3.6 50.6 20.9 NS 48.5 10.5 NS
Plasma albumin mass,
g/I.73 m2 108.9 10.9 120.0 25.2 NS 48.1 22.2 <0.001
Total body albumin mass,
g/i.73 m2 266.2 27.3 249.0 29.1 NS 92.1 44.6 <0.001
Extravascular albumin mass,
g/1.73 m2 157.0 20.7 130.0 26.2 NS 43.3 22.1 <0.001
Plasma albumin mass
Extravascular albumin mass 0.699 0.083 0.968 0.354 NS 1.187 0.402 NS
External albumin loss,
g/I.73 m2
Protein loss, g/i.73 m2
0
0
4.23 1.42
8.79 4.21
<0.001
<0.001
6.6 2.67
8.87 3.88
<0.05
NS
Catabolism, g/24 hr/i .73 m2 13.80 0.77 9.76 1.74 <0.001 6.48 1.97 <0.001
Synthesis, g/24 hr/i .73 m2 13.80 0.77 13.99 2.52 NS 13.56 2.8 NS
Results
Table 3 summarizes albumin homeostatic data for the 18
patients. Serum albumin concentration remained constant in all
patients except patient no. 4. In that patient, serum albumin
concentration rose from 2.6 to 3.2 g/dl in association with a 6.9-
kg weight loss. That loss was the result of negative fluid balance
achieved to obtain control of the patient's hypertension. Daily
peritoneal and urinary albumin losses did not vary significantly
during the study period in that patient. Albumin losses for the
group ranged from 2.98 g to 13.12 g/l.73 m2. Protein losses
ranged from 3.61 g to 23.6 gll.73 m2/24 hr. Despite those losses,
the plasma albumin pool and the ratio of plasma albumin to
extravascular albumin remained within the normal range in our
CAPD patients. The serum albumin concentration for the 18
CAPD patients was 3.7 0.5 g/dl with an extracorporeal
albumin loss of 5.46 2.70 g/1.73 m2/24 hr. Albumin synthesis
was increased above the normal range in two of our patients.
Table 4 compares the albumin homeostatic data in nine CAPD
subjects in whom albumin distribution and synthesis were
studied with those of five normal control subjects. Albumin
catabolism was significantly less in the patients than in the
control subjects.
Figure 1 shows a negative correlation between serum albumin
concentration and peritoneal albumin losses in 18 CAPD
patients.
Multiple linear regression analysis was performed in the nine
patients in whom albumin turnover studies were carried out to
determine whether or not plasma volume expansion made a
significant contribution to hypoalbuminemia, as we have shown
to be true in rats with chronic renal failure [14]. The relationship
between serum albumin concentration and both plasma volume
and external albumin loss was analyzed using multiple regres-
sion analysis [15].
Albumin concentration = 5.069 — (0.173 0.091)
x albumin loss (g/l.73 m2/24 hr)
— (0.0117 0.0062) >< plasma volume (mi/kg)
The SD of the regression was 0.221 (r = 0.9246, P < 0.001). The
partial correlation coefficients were for albumin loss (r =
0.8765, P < 0.002, and for plasma volume r = 0.8758, P =
0.002).
Figure 2 shows the change in specific radioactivity of I-
labeled albumin in the serum of one of our peritoneally dialyzed
patients. It also shows the relationship between the specific
radioactivity of albumin removed by peritoneal dialysis and the
plasma concentration of specific radioactivity of plasma albu-
min. Although Figure 2 was derived from only one patient, the
results were the same for all patients studied. It takes between 1
and 2 days before the peritoneal albumin specific radioactivity
equals the plasma albumin concentration. After that time, the
specific radioactivity of peritoneal albumin overshoots the
plasma level and remains slightly above the plasma value
thereafter.
Figure 3 shows the relationships among albumin synthesis,
albumin catabolism, and total extracorporeal loss of albumin.
Although catabolism remained constant, albumin synthesis
increased with increasing extracorporeal losses within the nine
patients.
Discussion
Our CAPD patients suffered large external losses of albumin
and other proteins well within the nephrotic range [11, 16—19].
Although the fall in serum albumin concentration was highly
significant in comparison to our control subjects, it was quite
small (0.9 g/dl). It is instructive to compare the state of albumin
metabolism in our CAPD patients with that of albumin metabo-
lism of some nephrotic patients studied by other investigators
[11, 16—19]. A characteristic of nephrotic syndrome is the
complete lack of correlation between serum albumin concentra-
tion and albuminuria or proteinuria [11, 16]. In CAPD patients,
there is a striking correlation between albumin losses and serum
albumin concentration, but the serum albumin concentration
falls only modestly with increasing extracorporeal losses. Part
(9) of the fall in serum albumin concentration is the result of plasma
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2—
Plasma albumin concentration =
4.5 — 0.148 (albumin loss)
r = 0.744
0 j
2 4 6 8
volume expansion. We have demonstrated previously that
serum albumin concentration in rats with chronic renal failure is
depressed independently by both external loss and by plasma
volume expansion [14]. This is also the case in patients on
CAPD. Plasma albumin mass, total albumin mass, and distribu..
tion of albumin were not different when the CAPD patients and
normal control subjects were compared.
Jensen et al [11] studied 30 nephrotic patients and reported a
mean urinary albumin loss of 6.60 2.67 gIl .73 m2/24 hr with a
serum albumin concentration of 1.54 0.68 gIdl. Six patients
studied by Kaitz [17] had a mean albumin loss of 6.9 3.4 g124
hr with a serum concentration of 2.28 1.14 gIdl. Six patients
studied by Bauman et al [18] had a mean urinary albumin loss of
6.43 3.39 g170 kg/24 hr with a serum albumin concentration of
2.90 0.94 gIdl. Five patients studied by Blahd, Fields, and
Goldman [19] had a mean urinary albumin loss of 7.53 2.24
g124 hr with a serum albumin concentration of 1.00 0.37 g/dl;
no weights were given for their patients. External albumin
losses for our 18 CAPD patients were 5.61 2.59 gIl.73 m2/24
hr. In no case was the difference between albumin lost by our 18
CAPD patients and that lost by the nephrotic patients in any of
the studies just cited statistically significant. In all cases the
serum albumin concentration was significantly higher in the
CAPD patients than in the nephrotic patients. The studies by
Jensen et al [11] and Gitlin, Janeway, and Fan [16] provide both
height and weight for their patients. The study by Jensen et a!
[1 1J is the largest study reported, and so their data can be more
readily compared with our own. Albumin excretion calculated
from their data and serum albumin concentration reported for
nephrotic patients are very similar to those reported by the
other groups and thus appear to be representative of the
nephrotic patient population. In contrast to CAPD patients,
nephrotic patients have a markedly reduced plasma albumin
pool. The extravascular pool is depleted to an even greater
extent [11, 16]. There are three potential mechanisms for
adapting to external albumin loss; these are as follows:
Time, days
Fig. 2. Specific radioactivity of serum (I, —) andperitoneal albumin(0, ) in patient no. 2 with chronic ambulatory peritoneal dialysis.
The rapid component (A) of this curve was extrapolated to zero time
(Point 1). Plasma volume is the ratio of injected dose in counts per
minute (CPM) to the extrapolation at the zero time of the 1251 plasma
curve expressed in CPM/ml. The terminal component (B) was used to
calculate the volume of distribution of albumin as described in Results.
(1) Albumin synthetic rate may be increased. Within our
CAPD patient population, albumin synthesis was increased
gram for gram with increasing external albumin loss. In one
study albumin synthesis in nephrotic children was increased
twofold over the control group [201, but the control group
consisted of patients who would be expected to have reduced
albumin synthesis [211 (one with anorexia nervosa, one with
cystic fibrosis, one with chronic liver disease, and one mentally
retarded child with undefined nutritional status). Within the
group of patients described by Jensen et al [111, albumin
synthesis tended to increase with increasing urinary albumin
losses. Bianchi et al [221 suggested that albumin synthesis
increases linearly with urinary albumin excretion in patients
with albuminuria approaching 33 g/day. They unfortunately did
not measure either urinary albumin or protein excretion direct-
ly, but calculated it from the ratio of bound to unbound 1251 in
the urine. If their patients did indeed excrete 33 g of albumin in
their urine per day, increased albumin synthesis must have
played an important role because reduction in albumin catabo-
lism to zero could only provide about 14 g of albumin for
external loss. They argued that the stimulus for increased
albumin synthesis in nephrotic patients is the depeletion of the
extravascular albumin pool. They are not alone in their hypoth-
esis that depletion of the extravascular albumin pool or of a
particular extravascular pool is of key importance in the regula-
tion of the rate of albumin synthesis. Rothschild et al [23] and
Oratz [24] identified an interstitial pool of albumin in the liver
that seemed to act as an oncostat. They demonstrated an
inverse relationship between the content of albumin in this
interstitial pool and the rate of albumin synthesis. If the
depletion of albumin from the interstitium is important in
producing increased albumin synthesis in some nephrotic pa-
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Fig. 3. Response of albumin synthesis (•, —) and albumin catabo-
lism (0, ) of chronic ambulatory peritoneal dialysis patients to
increasing extracorporeal albumin loss,
tients, depletion of the entire interstitial albumin pool in CAPD
patients cannot be the mechanism responsible for increased
albumin synthesis within that group of patients. The interstitial
albumin pool is normal in the CAPD patients, unlike in nephrot-
ic patients where it is depleted [11, 161.
(2) Albumin catabolism may be reduced and was reduced in
our patients as a group in comparison with control subjects.
Albumin catabolic rate did not vary within the CAPD patient
population when patients with larger albumin losses were
compared with those with lesser losses. It is, therefore, not
possible to tell whether or not the reduced albumin catabolic
rate was a response to external albumin loss. In examining the
data of Jensen et al [11] and Gitlin, Janeway, and Fan [16],
albumin catabolism was reduced in nephrotic patients also. The
difference between normal synthesis rates and depressed cata-
bolic rates provides the excess albumin that is lost through the
kidney in their patients. Historically, increased renal catabo-
lism of albumin is considered a major contributing factor in the
generation of hypoalbuminemia, but albumin catabolism is, in
fact, not increased in absolute terms. Absolute albumin catabol-
ic rate was greater in our CAPD patients than in Jensen's
nephrotic patients, and total albumin loss, through catabolism
and direct external losses, tended to be greater in our patients
than in their nephrotic patients. Since albumin catabolism was
in steady state in these patients, albumin synthesis also tended
to be greater in the CAPD patients.
(3) Albumin may be transferred from the extravascular com-
partment to the vascular compartment. This has been shown to
be important in the acute adaption of rats to albuminuria [251.
This process mobilizes a limited reserve of albumin but clearly
must play a role in nephrotic humans as evidenced by the
depleted extravascular albumin pool. This mechanism is not
important in CAPD patients because the extravascular pool is
normal.
Another principal difference between the CAPD patients and
nephrotic patients is the route of albumin loss. Nephrotic
patients filter serum proteins directly from the circulation so the
plasma compartment is depleted directly [26—29]. During perito-
neal dialysis, the plasma compartment is depleted of albumin
only indirectly. Bonomini, Zucchelli, and Mioli [301 demon-
strated that during the initiation of peritoneal dialysis there was
a pool of nonradioactive albumin that was mobilized after
injection of '251-labeled albumin into a peripheral vein. They
estimated this pool to be about 6 g, and presumably, it repre-
sents an interstitial pool of albumin. Our data are consistent
with this interpretation. The lag in the specific radioactivity of
albumin in dialysate behind that in plasma was due to a lag in
transport of albumin from the vascular compartment into the
interstitial compartment that was then depleted by the dialysis
procedure. The reason the specific radioactivity of albumin in
the dialysate was higher than that in plasma after day 2 was
because the interstitial pool in the abdomen represented albu-
min from the vascular compartment from an earlier time point
when the specific radioactivity of serum albumin was higher
than that in a blood sample obtained simultaneously when the
dialysate sample was collected. The albumin in the dialysate
came from the extravascular interstitial pool. Depletion of an
extravascular pool of albumin rather than a vascular pool might
be significant. If the rate of albumin synthesis is indeed regulat-
ed by an oncotically sensitive pool in the abdomen as proposed
by Rothschild et al [23] and Oritz [24], pentoneal dialysis might
act by depleting that pool directly and therefore directly stimu-
late albumin synthesis. In nephrotic patients this pool would be
depleted indirectly because the pool would be in equilibrium
with, but not directly contiguous with, the serum compartment.
Patients with the nephrotic syndrome would then be able to
increase the rate of albumin synthesis but at the expense of a
depleted plasma pool.
Clearly, there are other differences between the nephrotic
patients described by other investigators [11, 16—19] and our
CAPD patients. The CAPD patients have continuous peritoneal
absorption of glucose and the many endocrinologic and meta-
bolic perturbations of endstage renal disease. It may be argued
that patients with the nephrotic syndrome may have proteinuria
for long periods of time prior to study, but, to our knowledge,
there have been no studies to indicate that there is a qualitative
change in albumin metabolism in nephrotic patients as the
duration of albuminuria is prolonged. We found no difference in
albumin metabolism in CAPD patients who had been dialyzed
for up to 38 months. Other studies on CAPD patients have
failed to show deterioration of serum albumin concentration
with longer times on dialysis [31]. Many of our patients were
studied shortly after the onset of peritoneal dialysis. It might be
argued that a contributing mechanism of albumin homeostasis
in these patients was mobilization of the extravascular albumin
mass. Serum albumin concentration remained stable through
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the 4 weeks of study, as did peritoneal albumin losses. Serum
albumin concentration also remained stable for several months
after these studies were performed. These observations would
indicate that metabolic processes—decreases in catabolism or
increases in synthetic rate—replaced the albumin lost rather
than mobilization of a finite extravascular pool. When dialysis
patients with protein intakes of 1.53 glkg body wt were com-
pared with those who consumed less generous quantities of
protein, down to 0.85 g/kg body wt, or when diabetic patients
and patients with other forms of renal failure were compared,
their responses to albumin losses were indistinguishable. The
CAPD patients through combined mechanisms of increasing
albumin synthesis within the group in direct response to exter-
nal albumin loss and of reducing albumin catabolism in compar-
ison with control subjects accomodate for albumin losses with
little or no derangements in albumin concentration, pool size, or
distribution.
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